Svetlana Fayngerts
About Svetlana Fayngerts
Svetlana Fayngerts is a Senior Scientist in Translational Sciences at Adaptimmune US, where she has worked since 2017. She holds a PhD and has contributed to research on T-cell therapies for cancer, including SPEAR T-cells and ADP-A2M4 T-cells.
Work at Adaptimmune
Svetlana Fayngerts serves as a Senior Scientist in Translational Sciences at Adaptimmune, a role she has held since 2017. Based in Philadelphia, Pennsylvania, she focuses on advancing T-cell therapies for cancer. Her work includes significant contributions to the development of SPEAR T-cells, specifically targeting MAGE-A4, which is a critical area in cancer immunotherapy. Her expertise in translational sciences plays a vital role in bridging laboratory research with clinical applications.
Education and Expertise
Svetlana Fayngerts earned her Doctor of Philosophy degree from Novosibirsk State University, where she studied in the Department of Economics from 2001 to 2006. Prior to her doctoral studies, she completed her Master of Science and Bachelor of Science degrees at the same institution from 1996 to 2001. Additionally, she studied at the University of Pennsylvania for one year from 2012 to 2013. This educational background provides her with a strong foundation in both scientific research and economic principles.
Research Contributions
Svetlana Fayngerts has made notable contributions to cancer research, particularly in the field of T-cell therapies. She has co-authored case reports on the adoptive transfer of ADP-A2M4 T-cells in patients with synovial sarcoma. Her research on SPEAR T-cells targeting MAGE-A4 is significant for developing innovative treatments in oncology. These contributions highlight her commitment to advancing cancer therapies through rigorous scientific investigation.
Background
Svetlana Fayngerts has a diverse academic and professional background that combines economics and life sciences. Her extensive education in economics, coupled with her research in translational sciences, positions her uniquely within the field of cancer therapy development. Her career trajectory reflects a strong commitment to integrating economic principles with scientific research to enhance healthcare outcomes.